Park Place Capital Corp Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Park Place Capital Corp grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 37.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,078 shares of the medical equipment provider’s stock after buying an additional 291 shares during the quarter. Park Place Capital Corp’s holdings in Hologic were worth $84,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of HOLX. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Hologic during the fourth quarter worth $27,000. Massmutual Trust Co. FSB ADV lifted its position in shares of Hologic by 69.4% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 227 shares in the last quarter. Allworth Financial LP raised its holdings in Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 179 shares in the last quarter. Mather Group LLC. acquired a new stake in Hologic in the first quarter valued at $48,000. Finally, Toth Financial Advisory Corp raised its holdings in Hologic by 81.1% in the first quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 347 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HOLX has been the topic of several recent analyst reports. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Stephens initiated coverage on shares of Hologic in a report on Thursday. They issued an “overweight” rating and a $87.00 price target on the stock. JPMorgan Chase & Co. upped their price target on shares of Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Argus upped their price target on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Finally, Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and upped their price target for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $85.73.

Hologic Stock Performance

Shares of Hologic stock traded down $0.15 during trading on Monday, hitting $74.10. 1,153,347 shares of the stock were exchanged, compared to its average volume of 1,637,029. The stock’s fifty day moving average is $74.32 and its 200 day moving average is $74.32. The stock has a market cap of $17.29 billion, a PE ratio of 37.88, a P/E/G ratio of 2.47 and a beta of 0.99. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $82.45.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $0.98 by $0.05. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The company’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.06 earnings per share. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.08 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.